Last reviewed · How we verify
Metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation
Approved treatments
- Mekinist · Novartis
Mekinist works by blocking a specific enzyme called BRAF V600E, which is involved in the growth and spread of cancer cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation patent landscape — cliff calendar, originator estates, attackable patents
- Metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation treatment landscape brief
- Metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation treatment updates RSS
Frequently asked questions about Metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation
What drugs treat Metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation?
Tracked treatments include Mekinist.
What is the treatment for Metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation?
Standard treatment for Metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation includes Mekinist. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation patent cliff · Metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation CI report
- Treatment: Mekinist · Novartis
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing